PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented today at the annual EuroPCR Scientific Program in Paris by Joachim Schofer, M.D., of the Hamburg University Cardiovascular Center.
Renal denervation with the Vessix System is a minimally-invasive procedure in which a balloon catheter is fed into the arterial vascular system and positioned in the renal arteries, the major blood vessels that lead to the kidneys. The physician then delivers low-power radiofrequency (RF) energy to disrupt the nerves surrounding the renal arteries in which hyperactivity leads to uncontrolled high blood pressure.
"Tens of thousands of patients worldwide have blood pressure that is high and uncontrolled, putting them at significantly increased risk for a variety of cardiovascular diseases, including heart attack, stroke and kidney failure," said Professor Horst Sievert, M.D., Ph.D., director of the CardioVascular Center Frankfurt, Sankt Katharinen Hospital, in Frankfurt, Germany, and principal investigator in the REDUCE-HTN clinical program. "The interim data from REDUCE-HTN demonstrate that renal denervation with the Vessix System offers a significant and sustained blood pressure reduction in patients with uncontrolled hypertension. The familiar over-the-wire balloon platform of the Vessix System, the short procedure time and precise bipolar approach offer a significant step forward in the treatment of this challenging condition."
The REDUCE-HTN clinical program is evaluating the ability of the Vessix System to reduce blood pressure at six months as compared to the pre-treatment baseline blood pressure. Patients enrolled in the program are required to have a systolic blood pressure of at least 160 mmHg despite taking three or more antihypertensive medications.
Interim data highlights include:
- All patients underwent successful bilateral renal denervation treatment
- At the primary endpoint of six months, patients experienced a significant 27.6 mmHg reduction in systolic blood pressure (p<0.0001)
- No device-related adverse events or procedural renal artery complications were reported
- Long term efficacy was demonstrated, with a sustained 28.4 mmHg reduction in systolic blood pressure in the subset of patients for whom 12-month data are available
- Demonstrated success in treating various anatomies, including accessory renal arteries
- Demonstrated short renal denervation procedural time
"We believe that the familiar balloon catheter design of the Vessix System, intuitive user interface and unique bipolar technology make it the ideal choice for physicians," said Jeff Mirviss, president, Peripheral Interventions, Boston Scientific. "The interim REDUCE-HTN data support the expected long-term benefit of the Vessix System in reducing blood pressure, and we're excited to bring this advanced technology to physicians and their patients."
The Vessix System is a highly-differentiated, advanced renal denervation system that features an intuitive push-button interface, a short 30-second treatment time and an over-the-wire, balloon-based approach familiar to most cardiac and vascular specialists. The Vessix System has both CE Mark and TGA approval and is immediately available for sale in Europe, the Middle East, Australia, New Zealand and select markets in Asia. The Vessix System is not approved for use or sale in the United States.
To view the Multimedia News Release including videos, backgrounders and images, please click here: http://www.epresspack.net/boston-scientific-at-europcr-2013/news/vessix
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new our business plans, markets for our products, clinical trials and the importance of their results, product performance and importance, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Media Relations and Corporate Communications EMEA
Boston Scientific Corporation
Global Media Relations
Boston Scientific Corporation
Boston Scientific Corporation
SOURCE Boston Scientific Corporation